NasdaqGS:XERSPharmaceuticals
Should Xeris Biopharma’s Q1 Beat and Director Stock Moves Prompt a Fresh Look From XERS Investors?
In early June 2026, Xeris Biopharma director Marla Persky sold 15,500 shares under a Rule 10b5-1 plan, then received new restricted stock units and stock options as part of the company’s 2018 Stock Option and Incentive Plan.
Around the same time, Xeris Biopharma reported a 38% year-on-year increase in Q1 2026 revenue and earnings per share above market expectations, underscoring stronger-than-anticipated operating momentum.
Now we’ll examine how Xeris’s better-than-expected Q1 revenue...
